Key facts
- It has raised $3.1M.
- Notable investors include Innovation Authority, BizTEC, GoodPaper Ventures, MindUP.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Foresee Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Foresee Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Foresee Genomics
Developer of molecular diagnostics designed to improve the detection, treatment, and monitoring of cancers. The company's diagnostics kit combines molecular biology and computational analysis for identifying multiple cancer genomic markers and provides a reduction in diagnostic costs with comparison to present genomic tests, enabling physicians to support treatment response in patients by making genomic diagnostics accessible and affordable to everyone.
- Sector
- Healthcare
- HQ
- Highland Park, IL, United States
- Founded
- 2017
- Employees
- 7
- Website
- foreseegenomics.com/
- Ownership
- Privately Held (backing)
Foresee Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Foresee Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Foresee Genomics in its N-PORT filings yet. We sweep new filings monthly.